National Institute on Drug Abuse; Notice of Closed Meetings, 52916-52917 [2021-20581]
Download as PDF
<![CDATA[
52916
Federal Register / Vol. 86, No. 182 / Thursday, September 23, 2021 / Notices
Date: October 24–26, 2021.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: Porter Neuroscience Research
Center, Building 35A, 35 Convent Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nina F. Schor, MD, Ph.D.,
Deputy Director, National Institute of
Neurological Disorders and Stroke, NIH,
Building 31, Room 8A52, Bethesda, MD
20892, 301–496–9746, nina.schor@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: September 17, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20580 Filed 9–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Heart, Lung,
and Blood Advisory Council.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Heart, Lung,
and Blood Advisory Council.
Date: October 26, 2021.
Closed: 10:00 a.m. to 11:00 a.m.
Agenda: To Review and Evaluate Grant
Applications.
Place: National Institutes of Health,
Rockledge 1, 6705 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Open: 11:30 a.m. to 5:00 p.m.
Agenda: To Discuss Program Policies and
Issues.
Place: National Institutes of Health,
Rockledge 1,6705 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Virtual Access: The meeting will be
videocast and can be accessed from the NIH
Videocast. https://www.nhlbi.nih.gov/about/
advisory-and-peer-review-committees/
advisory-council. Please note, the link to the
videocast meeting will be posted within a
week of the meeting date.
Contact Person: Laura K. Moen, Ph.D.,
Director, Division of Extramural Research
Activities, National Heart, Lung, and Blood
VerDate Sep<11>2014
17:19 Sep 22, 2021
Jkt 253001
Institute, National Institutes of Health, 6705
Rockledge Drive, Room 206–Q, Bethesda, MD
20892, 301–827–5517, moenl@mail.nih.gov
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page:
www.nhlbi.nih.gov/meetings/nhlbac/
index.htm, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 17, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20584 Filed 9–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; SEP Limited Competition:
Clinical and Translational Science Award
(CTSA) Consortium-Wide Centers: Resources
for Rapid Demonstration and Dissemination
(U24 Clinical Trials Not Allowed).
Date: October 20, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20817, (301) 435–0813,
henriquv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: September 17, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20582 Filed 9–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploratory Studies to Investigate
Mechanisms of HIV Infection, Replication,
Latency, and/or Pathogenesis in the Context
of Substance Use Disorders (R61/R33—
Clinical Trial Not Allowed).
Date: October 26, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\23SEN1.SGM
23SEN1
52917
Federal Register / Vol. 86, No. 182 / Thursday, September 23, 2021 / Notices
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5843, trinh.tran@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Animal Genomics Program (U01—Clinical
Trial Not Allowed).
Date: November 5, 2021.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–4471, ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Assessing the Effects of Cannabinoids on
HIV-Associated Persistent Inflammation (R01
Clinical Trial Optional).
Date: November 19, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 17, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20581 Filed 9–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: Division of State
Programs—Management Reporting
Tool (DSP–MRT)
(OMB No. 0930–0354)—Revision
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA) Center for Substance Abuse
Prevention (CSAP) aims to monitor
several substance use prevention
programs through the DSP–MRT, which
reports data using the Strategic
Prevention Framework (SPF). Programs
monitored through the DSP–MRT
include: SPF-Partnerships for Success
(PFS), SPF- Prescription Drugs (Rx),
Prescription Drug Overdose (PDO), and
First Responder-Comprehensive
Addiction and Recovery Act (FR–
CARA). SAMHSA also proposed adding
a new program: Sober Truth on
Preventing Underage Drinking Act
Grants (STOP Act). This request for data
collection includes minor revisions
from a previously approved OMB
instrument.
Monitoring data using the SPF model
will allow SAMHSA’s project officers to
systematically collect data to monitor
their grant program. In addition to
assessing activities related to the SPF
steps, the performance monitoring
instruments covered in this statement
collect data to assess the following
grantee required specific performance
measures:
• Number of training and technical
assistance activities per funded
community provided by the grantee to
support communities
• Reach of training and technical
assistance activities (numbers served)
provided by the grantee
• Percentage of subrecipient
communities that submit data to the
grantee data system
• Number of subrecipient communities
that improved on one or more targeted
National Outcome Measures
• Number of grantees who integrate
Prescription Drug Monitoring Program
data into their program needs
assessment
• Number of naloxone toolkits
distributed
Revisions to this package include the
following:
• Inclusion of six performance targets
• Removal of outdated references
• Adjustments to the language in the
Disparities Impact Section to refine
response
ANNUALIZED DATA COLLECTION BURDEN
Number of
respondents
lotter on DSK11XQN23PROD with NOTICES1
Instrument
Responses per
respondent
Total number
of responses
Total
burden
hours
Hours per
response
Average
hourly
wage
Total
respondent
cost a
DSP–MRT .....................................................
PFS Supplemental ........................................
PDO/FR CARA Supplemental ......................
SPF Rx Supplemental ...................................
STOP Act Supplemental ...............................
521
253
109
26
133
4
1
2
4
1
2,084
253
218
104
133
3
1
1
1
1
6,252
253
218
104
133
$44.19
44.19
44.19
44.19
44.19
$276,276
11,180
9,633
4,596
5,877
FY2021–FY2024 Total ...........................
521
........................
........................
........................
6,960
........................
307,562
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
VerDate Sep<11>2014
17:19 Sep 22, 2021
Jkt 253001
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Carlos Graham,
Social Science Analyst.
[FR Doc. 2021–20608 Filed 9–22–21; 8:45 am]
BILLING CODE 4162–20–P
PO 00000
Frm 00046
Fmt 4703
Sfmt 9990
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 86, Number 182 (Thursday, September 23, 2021)]
[Notices]
[Pages 52916-52917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20581]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploratory Studies to Investigate Mechanisms of HIV
Infection, Replication, Latency, and/or Pathogenesis in the Context
of Substance Use Disorders (R61/R33--Clinical Trial Not Allowed).
Date: October 26, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 52917]]
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Animal Genomics Program (U01--Clinical Trial
Not Allowed).
Date: November 5, 2021.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
4471, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Assessing the Effects of Cannabinoids on HIV-
Associated Persistent Inflammation (R01 Clinical Trial Optional).
Date: November 19, 2021.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 17, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-20581 Filed 9-22-21; 8:45 am]
BILLING CODE 4140-01-P
